Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective.
暂无分享,去创建一个
[1] M Ferrari,et al. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. , 2008, Journal of biomechanics.
[2] C. Jaffe,et al. Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol. , 1990, The American journal of cardiology.
[3] S. Moein Moghimi,et al. Recognition by Macrophages and Liver Cells of Opsonized Phospholipid Vesicles and Phospholipid Headgroups , 2004, Pharmaceutical Research.
[4] Xu Wang,et al. Application of Nanotechnology in Cancer Therapy and Imaging , 2008, CA: a cancer journal for clinicians.
[5] Theresa M Allen,et al. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. , 2004, Biochimica et biophysica acta.
[6] M. Bawendi,et al. Renal clearance of quantum dots , 2007, Nature Biotechnology.
[7] Herbert J Meiselman,et al. Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients , 2007, Cancer.
[8] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[9] Kenneth A. Dawson,et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts , 2008, Proceedings of the National Academy of Sciences.
[10] T. Andresen,et al. Mechanistic study of the sPLA2-mediated hydrolysis of a thio-ester pro anticancer ether lipid. , 2009, Journal of the American Chemical Society.
[11] S. Davis,et al. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. , 1991, Biochemical and biophysical research communications.
[12] S. Moghimi,et al. Endothelial cells as therapeutic targets in cancer: new biology and novel delivery systems. , 2003, Critical reviews in therapeutic drug carrier systems.
[13] P. Cullis,et al. Drug Delivery Systems: Entering the Mainstream , 2004, Science.
[14] E Froehlich,et al. Dendrimers bind human serum albumin. , 2009, The journal of physical chemistry. B.
[15] P. Cullis,et al. β2-Glycoprotein I Is a Major Protein Associated with Very Rapidly Cleared Liposomes in Vivo, Suggesting a Significant Role in the Immune Clearance of "Non-self" Particles (*) , 1995, The Journal of Biological Chemistry.
[16] I. Venditti,et al. Lipolytic enzymes with improved activity and selectivity upon adsorption on polymeric nanoparticles. , 2007, Biomacromolecules.
[17] T. Allen. Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.
[18] S. Takeoka,et al. Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo. , 2007, Biomaterials.
[19] D. Ahmadvand,et al. Biological targeting and innovative therapeutic interventions with phage-displayed peptides and structured nucleic acids (aptamers). , 2011, Current opinion in biotechnology.
[20] Daniel Irimia,et al. Synthetic microvascular networks for quantitative analysis of particle adhesion , 2008, Biomedical microdevices.
[21] M Ferrari,et al. The adhesive strength of non-spherical particles mediated by specific interactions. , 2006, Biomaterials.
[22] O. Bourdon,et al. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. , 2001, Biomaterials.
[23] Taro Shimizu,et al. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[24] R. Mahley,et al. Chylomicron metabolism. Chylomicron uptake by bone marrow in different animal species. , 1989, The Journal of biological chemistry.
[25] S. Moghimi,et al. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug , 2008, Expert opinion on drug delivery.
[26] S. Moghimi,et al. Liposome-Mediated Triggering of Complement Cascade , 2008, Journal of liposome research.
[27] Ji-Ho Park,et al. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. , 2009, Biomaterials.
[28] T. Gray,et al. A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats. , 1997, Clinical science.
[29] Sara Linse,et al. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.
[30] Janos Szebeni,et al. Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] Robin Fåhræus,et al. THE VISCOSITY OF THE BLOOD IN NARROW CAPILLARY TUBES , 1931 .
[32] Samir Mitragotri,et al. Designer Biomaterials for Nanomedicine , 2009 .
[33] C. Lemere,et al. Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to β-Amyloid , 2003, The Journal of Neuroscience.
[34] Patrick Couvreur,et al. Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. , 2007, Biomacromolecules.
[35] D. Hochstrasser,et al. Colloidal carriers for intravenous drug targeting: Plasma protein adsorption patterns on surface‐modified latex particles evaluated by two‐dimensional polyacrylamide gel electrophoresis , 1993, Electrophoresis.
[36] S. Moghimi,et al. Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. , 2004, Biochimica et biophysica acta.
[37] Barbara Klajnert,et al. Haemolytic activity of polyamidoamine dendrimers and the protective role of human serum albumin , 2010, Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences.
[38] H. Dai,et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. , 2020, Nature nanotechnology.
[39] Joseph M. DeSimone,et al. Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.
[40] D. Peng,et al. HDL and immunomodulation: an emerging role of HDL against atherosclerosis , 2010, Immunology and cell biology.
[41] Robert Langer,et al. On firm ground: IP protection of therapeutic nanoparticles , 2010, Nature Biotechnology.
[42] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[43] Maurizio Prato,et al. Carbon-nanotube shape and individualization critical for renal excretion. , 2008, Small.
[44] A. C. Hunter,et al. Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[45] Weibo Cai,et al. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy , 2008, Proceedings of the National Academy of Sciences.
[46] Mauro Ferrari,et al. Design of bio-mimetic particles with enhanced vascular interaction. , 2009, Journal of biomechanics.
[47] Thomas Vorup-Jensen,et al. Curvature of Synthetic and Natural Surfaces Is an Important Target Feature in Classical Pathway Complement Activation , 2010, The Journal of Immunology.
[48] Robert Langer,et al. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. , 2009, Biomaterials.
[49] Thomas L Andresen,et al. Enzyme-triggered nanomedicine: Drug release strategies in cancer therapy (Invited Review) , 2010, Molecular membrane biology.
[50] B. Nilsson,et al. Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface. , 1993, Molecular immunology.
[51] D. Simberg,et al. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems , 2011, Expert opinion on drug delivery.
[52] Doriano Brogioli,et al. Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. , 2010, Biomaterials.
[53] Mauro Ferrari,et al. Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.
[54] Samir Mitragotri,et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[55] Jun Fang,et al. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.
[56] S Moein Moghimi,et al. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. , 2010, ACS nano.
[57] P. Cullis,et al. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. , 1992, The Journal of biological chemistry.
[58] J. Brash,et al. Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. , 2001, Biochimica et biophysica acta.
[59] Bo Nilsson,et al. C3 Adsorbed to a Polymer Surface Can Form an Initiating Alternative Pathway Convertase1 , 2002, The Journal of Immunology.
[60] D. Discher,et al. Shape effects of filaments versus spherical particles in flow and drug delivery. , 2007, Nature nanotechnology.
[61] A. Popel,et al. A two-phase model for flow of blood in narrow tubes with increased effective viscosity near the wall. , 2001, Biorheology.
[62] H. Dai,et al. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. , 2008, Molecular immunology.
[63] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[64] Magnus Bergkvist,et al. Paradoxical glomerular filtration of carbon nanotubes , 2010, Proceedings of the National Academy of Sciences.
[65] L. Munn,et al. Aberrant vascular architecture in tumors and its importance in drug-based therapies. , 2003, Drug discovery today.
[66] D. Devine,et al. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. , 1991, Journal of immunology.
[67] M Ferrari,et al. The receptor-mediated endocytosis of nonspherical particles. , 2008, Biophysical journal.
[68] H. Goldsmith,et al. Margination of leukocytes in blood flow through small tubes. , 1984, Microvascular research.
[69] D. Tzemach,et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma , 2000, Cancer.
[70] T. Andresen,et al. Activation of the Human Complement System by Cholesterol-Rich and PEGylated Liposomes—Modulation of Cholesterol-Rich Liposome-Mediated Complement Activation by Elevated Serum LDL and HDL Levels , 2006, Journal of liposome research.
[71] P. Couvreur,et al. Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2‐DE, CE and Protein Lab‐on‐chip® system , 2007, Electrophoresis.
[72] J Szebeni,et al. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.
[73] Stephanie E. A. Gratton,et al. The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.
[74] Poloxamer-188 revisited: a potentially valuable immune modulator. , 1996, Journal of the National Cancer Institute.
[75] S. Radford,et al. Nucleation of protein fibrillation by nanoparticles , 2007, Proceedings of the National Academy of Sciences.
[76] J. Weinstein,et al. Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins. , 1980, Journal of lipid research.
[77] G. Vercellotti,et al. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis , 1982 .
[78] J Szebeni,et al. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[79] S. Chow,et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer , 2003, Anti-cancer drugs.
[80] Samir Mitragotri,et al. Physical approaches to biomaterial design. , 2009, Nature materials.
[81] Dipak K. Sarker,et al. Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. , 2006, Journal of nanoscience and nanotechnology.
[82] Ya‐Ping Sun,et al. Covalently PEGylated carbon nanotubes with stealth character in vivo. , 2008, Small.
[83] Piet Gros,et al. Structure of C3b reveals conformational changes that underlie complement activity , 2006, Nature.
[84] T. Ishida,et al. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[85] S. Perkins,et al. Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation. , 1991, Journal of molecular biology.
[86] Iseult Lynch,et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.
[87] S. Moghimi. Mechanisms of splenic clearance of blood cells and particles : towards development of new splenotropic agents , 1995 .
[88] M. Ferrari,et al. A Theoretical Model for the Margination of Particles within Blood Vessels , 2005, Annals of Biomedical Engineering.
[89] Malcolm L. H. Green,et al. Complement activation and protein adsorption by carbon nanotubes. , 2006, Molecular immunology.
[90] Kapil Pant,et al. A physiologically realistic in vitro model of microvascular networks , 2009, Biomedical microdevices.
[91] Moghimi,et al. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity. , 1998, Advanced drug delivery reviews.
[92] M. Ferrari. Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.
[93] M. Gobbi,et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. , 2011, Biomaterials.
[94] K. Sou,et al. Bone marrow-targeted liposomal carriers , 2011, Expert opinion on drug delivery.
[95] M Ferrari,et al. Size and shape effects in the biodistribution of intravascularly injected particles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[96] S. Moghimi,et al. Capture of stealth nanoparticles by the body's defences. , 2001, Critical reviews in therapeutic drug carrier systems.
[97] P. Cossart. Host/pathogen interactions. Subversion of the mammalian cell cytoskeleton by invasive bacteria. , 1997, The Journal of clinical investigation.
[98] L. Harker. Platelets and vascular thrombosis. , 1994, The New England journal of medicine.
[99] J. Karp,et al. Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .
[100] Betty Y. S. Kim,et al. Current concepts: Nanomedicine , 2010 .
[101] Jing Zhao,et al. Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9. , 1993, The Journal of biological chemistry.
[102] D. Hourcade,et al. Properdin Can Initiate Complement Activation by Binding Specific Target Surfaces and Providing a Platform for De Novo Convertase Assembly1 , 2007, The Journal of Immunology.
[103] Arezou A Ghazani,et al. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. , 2006, Nano letters.
[104] Mauro Ferrari,et al. Design maps for nanoparticles targeting the diseased microvasculature. , 2008, Biomaterials.
[105] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[106] James H. Adair,et al. Nanoparticulate alternatives for drug delivery. , 2010, ACS nano.
[107] S. Moghimi,et al. Complement monitoring of carbon nanotubes. , 2010, Nature nanotechnology.
[108] J. C. Roberts,et al. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. , 1996, Journal of biomedical materials research.
[109] Samir Mitragotri,et al. Flow and adhesion of drug carriers in blood vessels depend on their shape: a study using model synthetic microvascular networks. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[110] T. Andresen,et al. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. , 2005, Progress in lipid research.
[111] S. Gordon,et al. Monocyte and macrophage heterogeneity , 2005, Nature Reviews Immunology.
[112] A. Weintraub,et al. Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2 , 2006 .
[113] D. Peer,et al. Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.
[114] Kenneth A. Dawson,et al. Protein–Nanoparticle Interactions , 2008, Nano-Enabled Medical Applications.
[115] S. Davis,et al. Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan‐stimulated rats , 1993, Journal of leukocyte biology.
[116] S Gordon,et al. Macrophage receptors and immune recognition. , 2005, Annual review of immunology.
[117] R. Gurny,et al. An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D,L-lactic acid) nanoparticles by human monocytes. , 1995, Life sciences.